## 留言板

 引用本文: 宋保军, 娄洁, 文清芝. 使用T-20治疗HIV-1患者的不同策略的数学建模与研究[J]. 应用数学和力学, 2011, 32(4): 400-416.
SONG Bao-jun, LOU Jie, WEN Qing-zhi. Modelling Two Different Therapy Strategies for Drug T-20 on HIV-1 Patients[J]. Applied Mathematics and Mechanics, 2011, 32(4): 400-416. doi: 10.3879/j.issn.1000-0887.2011.04.004
 Citation: SONG Bao-jun, LOU Jie, WEN Qing-zhi. Modelling Two Different Therapy Strategies for Drug T-20 on HIV-1 Patients[J]. Applied Mathematics and Mechanics, 2011, 32(4): 400-416.

## 使用T-20治疗HIV-1患者的不同策略的数学建模与研究

##### doi: 10.3879/j.issn.1000-0887.2011.04.004

###### 作者简介:宋保军(1959- ),男,美国人,副教授,博士(联系人.E-mail:songb@mail.montclair.edu).
• 中图分类号: O175.7

## Modelling Two Different Therapy Strategies for Drug T-20 on HIV-1 Patients

• 摘要: 通过建立数学模型,描述了HIV-1感染者使用抗病毒治疗药物——融合酶抑制剂(T-20)的治疗效果．使用脉冲微分方程描述了T-20的使用过程,并考虑了两种不同的药物消除动力学:一级消除动力学与米-曼(Michaelis-Menten)消除动力学．此模型是个非自治微分方程系统,主要关注其无病平衡态,并研究当接受治疗者在服药完全依从的治疗过程中无病平衡态的稳定性．分别针对药物剂量与服药间隔得到了使得无病平衡态稳定的阈值条件．此外,还研究了间歇治疗的效果．研究表明,间歇治疗的效果甚至可以比完全不治疗还要糟糕．
•  [1] Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART[J]. Journal of Antimicrobial Chemotherapy, 2003, 51(2): 213-217. [2] Trottier B, Walmsley S. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks[J]. Journal of Acquired Immune Deficiency Syndrome, 2005, 40(4): 413-421. [3] Liu S W, Wu S G, Jiang S B. Advancement in developing a new class of anti-AIDS drugs: HIV entry inhibitors[J]. Chinese Pharmacological Bulletin, 2005, 21(9): 1034-1040. [4] Castagna A, Biswas P, Beretta P, Lazzarin A. The appealing story of HIV entry inhibitors from discovery of biological mechanisms to drug development[J]. Drugs, 2005, 65(7): 879-904. [5] Clotet B, Raffi F, Cooper D, Delfraissy J F, Lazzarin A, Moyle G, Rockstroh J, Soriano V, Schapiro J. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations[J]. AIDS, 2004, 18(8): 1137-1146. [6] Perelson A S, Kirschner D E, Boer R D. Dynamics of HIV infection of CD4+ T cells[J]. Mathe Bios, 1992, 114(1): 81-125. [7] Perelson A S. Modeling the Interaction of the Immue System With HIV. Mathematical and Statistical Approaches to AIDS Epidemiology[M]. Berlin: Springer, 1989: 350-370. [8] Perelson A S, Nelson P W. Mathematical analysis of HIV-1 dynamics in vivio[J]. SIAM Rev, 1999, 41(1): 3-44. [9] Nowak M A, Bonhoeffer S, Shaw G M, May R M. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell population[J]. J Theor Biol, 1997, 184(2): 203-221. [10] Smith R J, Wahl L M. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects[J]. Bulletin of Mathematical Biology, 2005, 67(4): 783-813. [11] Smith R J, Wahl L M. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects[J]. Bulletin of Mathematical Biology, 2004, 66(5): 1259-1283. [12] Smith R J. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? [J]. Proc R Soc B, 2006, 273(1586): 617-624. [13] Wein L M, D’Amato R M, Perelson A S.Mathematical analysis of antiretroviral therapy aimed at HIV-1: eradication or maintenance of low viral loads[J]. J Theor Biol, 1988, 192(1): 81-98. [14] Nowak M A, May R M. Virus Dynamics[M]. Oxford:Oxford University Press, 2000. [15] Nelson P W, Murray J D, Perelson A S. A model of HIV-1 pathogenesis that includes an intracellular delay[J]. Math Biosci, 2000, 163(2): 201-215. [16] Wolfgang H, McNerney G P, Chen P, Dale B M, Gordon R E, Chuang F Y S, Li X, Asmuth D M, Huser T, Chen B K. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses[J]. Science, 2009, 323(5922): 1743-1747. [17] Lifson J D, Feinberg M B, Reyes G R, Rabin L, Banapour B, Chakrabarti S, Moss B, Wong-Staal F, Steimer K S, Engleman E G. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein[J].Nature, 1986, 323(6090): 725-728. doi: 10.1038/323725a0 [18] Sodroski J, Goh W C, Rosen C, Campbell K, Haseltine W A. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity[J]. Nature, 1986, 322(6078): 470-474. doi: 10.1038/322470a0 [19] Levy J. HIV and the Pathogenesis of AIDS[M]. Washington DC: American Society for Microbiology, 2007. [20] Sato H, Orenstein J, Dimitrov D, Martin M. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles[J]. Virology, 1992, 186(2): 712-724. [21] Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives[J]. J Pharmacokin Biopharm, 2006, 33(3): 227-279. [22] Wagner J G. A modern view of pharmacokinetics[J]. J Pharmacokin Biopharm, 1973: 1(5): 363-401. [23] Wen Q, LOU Jie. The global dynamics of a model about HIV-1 infection in vivo[J]. Ricerche di Matematica, 2009, 58(1): 77-90. [24] Ma Z, Song B, Hallam T G. The threshold of survival for systems in a fluctuating environment[J]. Bull Math Biol, 1989, 51(3): 311-323.

##### 计量
• 文章访问数:  1049
• HTML全文浏览量:  45
• PDF下载量:  828
• 被引次数: 0
##### 出版历程
• 收稿日期:  2010-05-10
• 修回日期:  2011-02-21
• 刊出日期:  2011-04-15

/

• 分享
• 用微信扫码二维码

分享至好友和朋友圈